Sara M Mangsbo

List of Publications by Year
in descending order

64	2,167	218677	243625
papers	citations	26 h-index	44 g-index

70	70	70	3698
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVIDâ€19. Journal of Internal Medicine, 2022, 291, 72-80.	6.0	47
2	SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PLoS ONE, 2022, 17, e0262169.	2.5	29
3	Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Vaccines, 2022, 10, 359.	4.4	11
4	Longâ€term SARSâ€CoVâ€2â€specific and crossâ€reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. Immunity, Inflammation and Disease, 2022, 10, e595.	2.7	6
5	Impact of SARSâ€CoVâ€2 infection on vaccineâ€induced immune responses over time. Clinical and Translational Immunology, 2022, 11, e1388.	3.8	20
6	Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab. JAMA Network Open, 2022, 5, e2211497.	5.9	20
7	Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. , 2022, 10, e004345.		15
8	Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. International Immunopharmacology, 2021, 90, 107226.	3.8	6
9	Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA - Journal of the American Medical Association, 2021, 325, 2015.	7.4	286
10	Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. Cancers, 2021, 13, 3116.	3.7	17
11	Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations. PLoS ONE, 2021, 16, e0253178.	2.5	4
12	Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nature Communications, 2021, 12, 4127.	12.8	59
13	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. Frontiers in Immunology, 2021, 12, 682492.	4.8	18
14	Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. EBioMedicine, 2021, 70, 103523.	6.1	42
15	An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. PLoS ONE, 2021, 16, e0258041.	2.5	10
16	Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells. New Biotechnology, 2021, 65, 9-19.	4.4	12
17	Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Toxicology Reports, 2020, 7, 768-771.	3.3	79
18	Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy. OncoImmunology, 2020, 9, 1730538.	4.6	23

#	Article	IF	Citations
19	Tumor localized agonistic anti-CD40 therapy and beyond. Expert Opinion on Biological Therapy, 2020, 20, 215-217.	3.1	5
20	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Frontiers in Immunology, 2020, 11, 615240.	4.8	59
21	BCGâ€induced cytokine release in bladder cancer cells is regulated by Ca 2+ signaling. Molecular Oncology, 2019, 13, 202-211.	4.6	9
22	Abstract A128: Tumor endothelial cells say IDO to CD40-stimulating immunotherapy. , 2019, , .		0
23	Abstract A137: The innate/adaptive immune response triggered in response to local immunotherapy of orthotopically growing bladder cancer tumors. , 2019, , .		0
24	Abstract 501: Early immunological events in the periphery and the TME following a local immunostimulating instillation into the bladder in the MB49 orthotopic model. , 2019, , .		0
25	Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics. International Immunopharmacology, 2018, 54, 1-11.	3.8	6
26	Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. Molecular Immunology, 2018, 93, 115-124.	2.2	15
27	Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System. Journal of Immunology, 2018, 201, 87-97.	0.8	16
28	Abstract 5638: A tetanus-way of improving synthetic long peptide tumor vaccination. , 2018, , .		0
29	Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment. Gene Therapy, 2017, 24, 92-103.	4.5	56
30	Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunology, Immunotherapy, 2017, 66, 1-7.	4.2	33
31	Local checkpoint inhibition of CTLAâ€4 as a monotherapy or in combination with antiâ€PD1 prevents the growth of murine bladder cancer. European Journal of Immunology, 2017, 47, 385-393.	2.9	64
32	Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. Oncotarget, 2017, 8, 78573-78587.	1.8	5
33	Abstract 1693: T cell responses to peptide-epitopes can be boosted by immune complexes of circulating anti-tetanus antibodies. , 2017, , .		0
34	Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. British Journal of Cancer, 2016, 114, 872-880.	6.4	41
35	Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget, 2016, 7, 50277-50289.	1.8	36
36	Selective FcÎ³R engagement by human agonistic anti-CD40 antibodies. Translational Cancer Research, 2016, 5, S839-S841.	1.0	1

#	Article	IF	Citations
37	Abstract B103: Intralesional administration of CTLA-4 blocking monoclonal antibodies as a means to optimize bladder cancer therapy. , 2016, , .		0
38	Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64+ cells. Scientific Reports, 2015, 5, 18308.	3.3	4
39	The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cellâ€“Dependent Tumor Immunity. Clinical Cancer Research, 2015, 21, 1115-1126.	7.0	79
40	The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. Molecular Cancer Therapeutics, 2015, 14, 1181-1191.	4.1	71
41	Kick-starting the cancer-immunity cycle by targeting CD40. OncoImmunology, 2015, 4, e1011484.	4.6	14
42	Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. OncoImmunology, 2014, 3, e27614.	4.6	70
43	Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer. OncoImmunology, 2014, 3, e27400.	4.6	11
44	CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Therapy, 2014, 21, 95-102.	4.6	20
45	The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. Journal of Neuroimmunology, 2014, 277, 153-159.	2.3	26
46	A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells. Journal of Immunotherapy, 2014, 37, 155-162.	2.4	3
47	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. Cancer Immunology Research, 2014, 2, 80-90.	3.4	78
48	Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 141.	2.3	0
49	The use of multiplex platforms for absolute and relative protein quantification of clinical material. EuPA Open Proteomics, 2014, 3, 37-47.	2.5	30
50	FcÎ³RIIb on Myeloid Cells Rather than on B Cells Protects from Collagen-Induced Arthritis. Journal of Immunology, 2014, 192, 5540-5547.	0.8	14
51	Tâ€cell responses after haematopoietic stem cell transplantation for aggressive relapsingâ€“remitting multiple sclerosis. Immunology, 2013, 140, 211-219.	4.4	32
52	FcÎ³RIIb on Myeloid Cells and Intrinsic Renal Cells Rather than B Cells Protects from Nephrotoxic Nephritis. Journal of Immunology, 2013, 190, 340-348.	0.8	18
53	FcÎ³ Receptor IIb Strongly Regulates FcÎ³ Receptor-Facilitated T Cell Activation by Dendritic Cells. Journal of Immunology, 2012, 189, 92-101.	0.8	56
54	Circulating specific antibodies enhance systemic crossâ€priming by delivery of complexed antigen to dendritic cells in vivo. European Journal of Immunology, 2012, 42, 598-606.	2.9	39

#	Article	IF	Citations
55	Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone. Molecular Immunology, 2012, 50, 49-56.	2.2	15
56	PHARMACOKINETICS AND TOXICITY OF INTRAVESICAL TMXâ€101: A PRECLINICAL STUDY IN PIGS. BJU International, 2011, 108, 1214-1215.	2.5	1
57	Both CD4⁺â€ƒFoxP3⁺ and CD4⁺â€ƒFoxP3^{â^'} T cells from patients with Bâ€cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology, 2011, 133, 296-306.	4.4	40
58	Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy. Journal of Immunotherapy, 2010, 33, 225-235.	2.4	171
59	AdCD40L Immunogene Therapy for Bladder Carcinomaâ€"The First Phase I/IIa Trial. Clinical Cancer Research, 2010, 16, 3279-3287.	7.0	89
60	Resolvin E1 Reduces Proinflammatory Markers in Human Pancreatic Islets in vitro. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 237-244.	1.2	29
61	Tumor-Specific Bacteriophages Induce Tumor Destruction through Activation of Tumor-Associated Macrophages. Journal of Immunology, 2009, 182, 3105-3111.	0.8	102
62	Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects. Journal of Immunology, 2009, 183, 6724-6732.	0.8	37
63	CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity. Journal of Immunotherapy, 2008, 31, 34-42.	2.4	45
64	An Adaptable Antibodyâ€Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies. Advanced Therapeutics, 0, , 2200008.	3.2	0